RxDoctor Payments Data

Lily Liu, MD

Internal Medicine · Cambridge, MANPI 1245435163

Payments from drug & device makers

$1,346in general payments, 2019–2025

Across 75 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$259
  • Pfizer$184
  • Boehringer Ingelheim$172
  • Gilead$120
  • AstraZeneca$106
  • Lilly USA, LLC$98
  • plus $407 from 11 others

What the payments were for

  • Food & beverage$1,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,346 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$53,679
Medicare patients
188
Services billed
2,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$42,419
TrulicityDulaglutide27$35,673
CreonLipase/Protease/Amylase14$33,918
EliquisApixaban34$29,229
XareltoRivaroxaban21$23,947
JardianceEmpagliflozin22$17,167
MyrbetriqMirabegron16$15,464
Synjardy XrEmpagliflozin/Metformin Hcl11$14,514
AbrysvoRsv Vacc, Pref A And Pref B/Pf40$12,192
JanuviaSitagliptin Phosphate12$10,699
TradjentaLinagliptin14$9,390
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$9,240
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,014
Atorvastatin Calcium483$6,868
Estradiol45$4,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$42,41940 claims
PfizerEliquis, Abrysvo$184$41,42174 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$172$41,07147 claims
Lilly USA, LLCTrulicity$98$35,67327 claims
AbbVieCreon$38$33,91814 claims
Johnson & JohnsonXarelto$67$23,94721 claims
MerckJanuvia$42$10,69912 claims
GSKTrelegy Ellipta, Arnuity Ellipta$60$9,74024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Cambridge

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →